MyOme Joins Mayo Clinic Platform_Accelerate Cohort to Advance Preventative Care
Access to De-Identified Clinical Data Will Help MyOme Scale Its Artificial Intelligence Solutions MENLO PARK, Calif., Aug. 12, 2025 /PRNewswire/...
Cancer
Apriori Bio Announces Collaboration with the Francis Crick Institute
Apriori to leverage foundational insights from the Crick's Legacy Study to further validate Octavia™ platform's ability to predict viral evolution...
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Click here to registerCompany plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter...
MIRA Pharmaceuticals’ Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in...
Izotropic Introduces New Corporate Website & Brand Identity
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3)...
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12,...
NASA’s SpaceX Crew-10 Returns Safely After Completing Dozens of ISS National Lab-Sponsored Investigations
Astronauts wrap up mission after supporting research that could lead to new cancer treatments, more lifelike robotics, space debris removal,...
Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering
Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025...
Flow Cytometry Market worth US$9.85 billion in 2033 with 8.7% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The global Flow Cytometry Market, valued at US$4.87 billion in 2024 stood at US$5.06...
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4...
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented...
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected...
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation...
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical...
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients...
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage...